CD271 Targeted Near-Infrared Photoimmunotherapy for Local Depletion of Cancer Stem Cells.

Area of Science:

• Oncology
• Immunotherapy
• Biotechnology

Background:

• Cancer stem cells (CSCs) drive tumor recurrence and metastasis due to their self-renewal and resistance to conventional therapies.
• Targeting CSCs is essential for effective cancer treatment and preventing disease progression.
• Near-infrared photoimmunotherapy (NIR-PIT) offers a cell-selective approach to cancer treatment.

Purpose of the Study:

• To evaluate the efficacy of NIR-PIT targeting CD271, a marker for cancer stem cells, in head and neck cancers.
• To compare the effectiveness of CD271-targeted NIR-PIT with EGFR-targeted NIR-PIT.
• To establish CD271-targeted NIR-PIT as a viable strategy for cancer stem cell therapy.

Main Methods:

• Utilized two human head and neck cancer cell lines (HPCM2 and HSC-3).
• Administered NIR-PIT using antibody-photoabsorber (IR700) conjugates targeting CD271.
• Conducted in vitro and in vivo experiments, including mouse models, to assess treatment efficacy.
• Compared CD271-targeted NIR-PIT with Epidermal Growth Factor Receptor (EGFR)-targeted NIR-PIT.

Main Results:

• Demonstrated the efficacy of NIR-PIT in depleting CD271-positive cancer stem cells in both in vitro and in vivo settings.
• Showed that CD271-targeted NIR-PIT was effective even with lower cell-surface expression compared to EGFR.
• Achieved comparable therapeutic outcomes between CD271-targeted and EGFR-targeted NIR-PIT in mouse models.

Conclusions:

• CD271-targeted NIR-PIT is an effective strategy for eliminating cancer stem cells in head and neck cancers.
• This approach holds significant potential for improving cancer treatment outcomes by targeting CSCs.
• This study represents the first demonstration of CD271-targeted NIR-PIT, paving the way for future CSC-targeted therapies.